Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study.
Ontology highlight
ABSTRACT: Clinical trials of cell-based therapies for heart failure have resulted in significant strides forward in our understanding of the potential the failing heart has for regeneration and repair. Yet, two decades on, the need for novel cell-based therapies for heart failure has never been greater. The DREAM-HF trial, which was presented as a late-breaking trial at the American Heart Association Scientific Sessions 2021 did not meet the primary heart failure outcome, but did show a large, clinically significant reduction in major adverse cardiovascular events (MACE) in patients receiving cells, an effect that was most pronounced in patients with evidence of maladaptive inflammation. These results represent an important step forward in our understanding of how cell-based therapies can exert bene
SUBMITTER: Johnston PV
PROVIDER: S-EPMC10978179 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA